journal article·2025-12-10Open access

Long-Term Stabilization and Storage of Peptide-Based Coacervate through Tyrosine-Rich Sequences and Polyphenol Network

Mohammad Souri, Moumita Halder, Lubna Amer, Yong Hua, Benjamin Lam, Wonjun Yim, Zhicheng Jin, Jesse V. Jokerst

Nano Letters· Volume 25· Issue 49

Abstract

Peptide-based coacervates are biocompatible and tunable but inherently unstable due to weak, reversible noncovalent interactions, making them vulnerable to stress from pH and temperature. This is especially difficult for coacervates used in commercial products with low-temperature storage or lyophilization. We engineered lyophilization-tolerant nanocoacervates by incorporating aromatic tyrosine residues into oligopeptide [(YR) 2 R 10 + (YR) 2 D 10 ] and reinforcing them with tannic acid (TA). This approach leverages π–π stacking, cation−π interactions, hydrogen bonds, and electrostatic interactions to create a stabilized network. The coacervates maintain their structure, count (10 7 particles/mL), size (<500 nm), and morphology after exposure to ionic strength of 10–100 mM, pH 3–10, elevated temperatures of 25–80 °C, biological media, and, crucially, freeze drying/rehydration. The study confirms that all interactions are essential for recovery from lyophilization. This is the first peptide-based coacervate system with lyophilization tolerance, supporting scalable applications in drug delivery, biostabilization, and regenerative medicine without cold-chain storage.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Supramolecular Self-Assembly in Materials · Polymer Surface Interaction Studies · Protein Hydrolysis and Bioactive Peptides

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Aiiso Yufeng Li Family Department of Chemical and Nano Engineering

University of California, San Diego

Materials Science and Engineering Program

Department of Chemical Engineering

Massachusetts Institute of Technology

Department of Chemistry

Georgia State University

Funding

National Institutes of Health

References (53)

Show source-provided references
1. 10.1038/s44222-023-00133-610.1038/s44222-023-00133-6 ↗
2. 10.1021/acs.iecr.3c0383010.1021/acs.iecr.3c03830 ↗
3. 10.1039/D0CS00307G10.1039/D0CS00307G ↗
4. 10.1021/acsami.5c0477510.1021/acsami.5c04775 ↗
5. 10.1021/acs.accounts.3c0068910.1021/acs.accounts.3c00689 ↗
6. 10.1021/acsnano.3c0425910.1021/acsnano.3c04259 ↗
7. 10.1038/s41467-024-54463-z10.1038/s41467-024-54463-z ↗
8. 10.1038/s41467-024-51218-810.1038/s41467-024-51218-8 ↗
9. 10.1038/s41467-023-44278-910.1038/s41467-023-44278-9 ↗
10. 10.1021/jacs.4c1788010.1021/jacs.4c17880 ↗
11. 10.1007/s13346-023-01477-710.1007/s13346-023-01477-7 ↗
12. 10.1021/acs.biomac.3c0004310.1021/acs.biomac.3c00043 ↗
13. 10.1021/jacs.3c0774810.1021/jacs.3c07748 ↗
14. 10.1016/j.carbpol.2025.12388010.1016/j.carbpol.2025.123880 ↗
15. 10.1016/j.jcis.2025.13782610.1016/j.jcis.2025.137826 ↗
16. 10.1021/acsami.3c0072710.1021/acsami.3c00727 ↗
17. 10.1021/jacs.4c1446910.1021/jacs.4c14469 ↗
18. 10.1038/s41467-024-53699-z10.1038/s41467-024-53699-z ↗
19. 10.1002/adma.20220291310.1002/adma.202202913 ↗
20. 10.1021/jacs.1c0114810.1021/jacs.1c01148 ↗
21. 10.1039/C4TB01213E10.1039/C4TB01213E ↗
22. 10.3390/pharmaceutics1311192410.3390/pharmaceutics13111924 ↗
23. 10.1021/la303211b10.1021/la303211b ↗
24. 10.1021/acsbiomaterials.4c0110510.1021/acsbiomaterials.4c01105 ↗
25. 10.1021/acs.biomac.8b0086310.1021/acs.biomac.8b00863 ↗
26. 10.1002/advs.20180125510.1002/advs.201801255 ↗
27. 10.1021/jp050418p10.1021/jp050418p ↗
28. 10.1021/la015697w10.1021/la015697w ↗
29. 10.1039/C6RA10889J10.1039/C6RA10889J ↗
30. 10.1007/s12010-015-1613-310.1007/s12010-015-1613-3 ↗
31. 10.1016/j.progpolymsci.2024.10190810.1016/j.progpolymsci.2024.101908 ↗
32. 10.1039/D1RA07657D10.1039/D1RA07657D ↗
33. 10.1021/acsomega.2c0167910.1021/acsomega.2c01679 ↗
34. 10.1007/s00289-020-03160-010.1007/s00289-020-03160-0 ↗
35. 10.1039/C6NJ00185H10.1039/C6NJ00185H ↗
36. 10.1021/acs.jpcb.4c0852610.1021/acs.jpcb.4c08526 ↗
37. 10.1038/s41598-018-20669-710.1038/s41598-018-20669-7 ↗
38. 10.3390/biomedicines1012327610.3390/biomedicines10123276 ↗
39. 10.1002/ange.20170416210.1002/ange.201704162 ↗
40. 10.1093/nar/gkm21010.1093/nar/gkm210 ↗
41. 10.1016/j.ijpharm.2023.12305110.1016/j.ijpharm.2023.123051 ↗
42. 10.3109/08982104.2014.99202310.3109/08982104.2014.992023 ↗
43. 10.2147/IJN.S12306210.2147/IJN.S123062 ↗
44. 10.1016/j.ijpharm.2023.12308410.1016/j.ijpharm.2023.123084 ↗
45. 10.1016/j.jconrel.2016.01.03410.1016/j.jconrel.2016.01.034 ↗
46. 10.1016/j.ejpb.2021.10.01410.1016/j.ejpb.2021.10.014 ↗
47. 10.34133/bmr.000510.34133/bmr.0005 ↗
48. 10.1016/j.isci.2022.10512710.1016/j.isci.2022.105127 ↗
49. 10.1021/acsami.5c0972610.1021/acsami.5c09726 ↗
50. 10.1039/c2fo00006g10.1039/c2fo00006g ↗
51. 10.3389/fnut.2024.137140110.3389/fnut.2024.1371401 ↗
52. 10.3390/antiox1208157710.3390/antiox12081577 ↗
53. 10.1016/j.tifs.2023.10419310.1016/j.tifs.2023.104193 ↗